Eli Lilly LLY Other Receivables
Other Receivables at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's other receivables?
- Eli Lilly (LLY) reported other receivables of $2.75B in Q1 2026.
- How has Eli Lilly's other receivables changed year-over-year?
- Eli Lilly's other receivables increased by 39.7% year-over-year, from $1.97B to $2.75B.
- What is the long-term trend for Eli Lilly's other receivables?
- Over 5 years (2020 to 2025), Eli Lilly's other receivables has grown at a 17.8% compound annual growth rate (CAGR), from $1.05B to $2.4B.
- What does other receivables mean?
- This represents miscellaneous claims for cash or other assets not classified under standard trade accounts receivable. It often includes tax refunds, interest receivables, or non-core operational claims. Monitoring this helps identify potential hidden liquidity issues or delays in cash conversion.